Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?

Shyamkumar, Krishnan, Hirsh, Jack, Bhagirath, Vinai C, Sinha, Smita, Xu, Ke, Ginsberg, Jeffrey S, Díaz, Rafael, Eikelboom, John W and Chan, Noel C (2020) Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? Future cardiology. ISSN 1744-8298. This article is available to all UHB staff and students via Ask Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://www.futuremedicine.com/loi/fca

Abstract

Until recently, attempts to improve the benefit of aspirin by adding another antithrombotic agent have not resulted in a mortality reduction in patients with chronic symptomatic atherosclerosis. In this population, COMPASS is the only one among six trials to show a significant mortality reduction, thereby providing evidence of a clear net clinical benefit with the combination of low-dose rivaroxaban plus aspirin. In this systematic review, we sought to determine whether the mortality benefit of the combination arm in COMPASS is best explained by greater statistical power or by a more favorable efficacy-safety profile than the other regimens evaluated in patients with chronic symptomatic atherosclerosis.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via Ask Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WG Cardiovascular system. Cardiology
WH Haemic and lymphatic systems. Haematology
WL Nervous system. Neurology
Divisions: Emergency Services > Cardiology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 26 Jun 2020 14:50
Last Modified: 26 Jun 2020 14:50
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3211

Actions (login required)

View Item View Item